Physician profile
Christopher M Lebo
NPI 1477558823
$5,245.42
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,431 · 2020: $1,054 · 2021: $1,546 · 2022: $1,215.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $859.26 | 2019-2022 | |
| Novo Nordisk INC | $646.67 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $555.26 | 2019-2022 | |
| Lilly USA, LLC | $386.60 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $371.26 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $345.21 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $210.63 | 2021-2022 | |
| Amgen INC. | $200.04 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $173.33 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $138.02 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $137.42 | 2021-2022 | |
| Astellas Pharma US INC | $137.00 | 2019 | |
| Abbvie INC. | $117.77 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.98 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $112.61 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $111.43 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $85.04 | 2021-2022 | |
| Amarin Pharma, INC. | $73.29 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $64.81 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $59.73 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $50.26 | 2022 | |
| Mylan Specialty L.P. | $44.94 | 2020-2021 | |
| Glaxosmithkline, LLC. | $43.13 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $42.97 | 2019 | |
| Abbott Laboratories | $42.29 | 2022 | |
| Scilex Pharmaceuticals INC. | $37.28 | 2019 | |
| Gilead Sciences, INC. | $17.23 | 2020 | |
| Biodelivery Sciences International, INC. | $15.59 | 2021 | |
| Zimmer Biomet Holdings, INC. | $13.65 | 2021 | |
| Genentech USA, INC. | $13.63 | 2019 | |
| Idorsia Pharmaceuticals US INC | $12.14 | 2022 | |
| Allergan, INC. | $10.95 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Lebo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.